Exact Sciences Corp. announced that it generated revenue of $523 million for the third quarter that ended Sept. 30, compared to $456 million for the same period in 2021. Full-year revenue for the cancer screening and diagnostic test company grew by $33 million and operating expenses decreased by $113 million. Screening revenue for products like Cologuard was $360.8 million, an increase of 29%. Adjusted EBITDA profitability is now expected in the third quarter of 2023 rather than the previous target of 2024.
Following layoff reports, Exact Sciences announces Q3 revenue up
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
